Global Peptide Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2029
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global Peptide Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2029 Reports Findings & Highlights:
Once overshadowed by small molecule and large protein based therapeutics, peptides have emerged as the new growth frontier of the pharmaceutical realm in the recent years. They have demonstrated therapeutic, diagnostic and theranostic properties, ushering in a new era of precision medicine. These adaptable molecules serve a critical role in treating a wide range of medical conditions by providing targeted therapeutic interventions. Beyond their treatment prowess, peptides illuminate the diagnostic landscape, serving as beacons in the detection of specific biomarkers and diseases. The convergence of therapeutic and diagnostic capabilities gives rise to the evolutionary concept of theranostics, where peptides act as both healers and guides, navigating the path toward personalized and effective healthcare solutions.
The continuous evolution of peptide drug development is fuelled by advancements in research and technology. Combinatorial chemistry and high-throughput screening have aided in the discovery of new peptide sequences with medicinal promise. Furthermore, advances in peptide synthesis processes have increased manufacturing efficiency, addressing historical issues with scalability and cost-effectiveness. The integration of computational tools and structure biology in peptide design has sped up the identification of lead compounds, reducing the time required for drug development.
The incorporation of artificial intelligence in peptide drug development has ushered in a new era of efficiency and innovation. Machine learning algorithms analyze vast datasets, predicting peptide structures with high binding affinities and enhancing the success rate of drug candidates. Additionally, AI helps in the identification of potential adverse events and optimization of pharmacokinetic properties, contributing to the overall quality of peptide therapeutics. Pharmaceutical companies such as ProteinQure have developed an extensive portfolio of peptide therapeutics using computational tools, while others like Space Peptides provide contract services to grant access to their machine learning and AI tools to design and produce premium peptide drugs.
The escalating interest of large pharmaceutical companies in peptide drugs is evident from the rapidly expanding global pipeline of peptide therapeutics. In addition, a surge of collaborations and strategic partnerships has been observed in the recent months within the pharmaceutical industry, some of these involving prominent pharmaceutical companies including Eli Lilly and AstraZeneca. Recognizing the potential of peptides to address unmet medical needs, prominent companies are aggressively seeking to expand their peptide portfolios through joint ventures, licensing agreements and acquisitions, which allow resource pooling and utilization of combined knowledge, thereby accelerating the development and commercialization of peptide drugs.
Peptide drugs are expected to play a significant role in the future landscape of the global pharmaceutical market. The growing understanding of disease causes at molecular levels coincides with the precision targeting abilities of peptides, making them a cornerstone in personalized medicine. Continuous advances in peptide engineering, together with the incorporation of AI, will almost certainly result in the development of highly effective and well-tolerated treatments. As the pharmaceutical industry move toward patient-centric paradigm, the adaptability and specificity of peptide drugs positions them as frontrunners in addressing the shifting healthcare landscape. Peptides’ adaptability across therapeutic areas, paired with their good safety rating, makes them an appealing choice for pharmaceutical companies seeking to fulfil patients’ medical diverse needs.
In conclusion, the journey through the realm of peptide drugs reveals an extensive array of innovation and potential. As we approach a new era in pharmaceuticals, peptides appear as more than merely therapeutic and diagnostic agents, but also as forerunners of a paradigm shift in healthcare. Peptides will play a crucial role in personalized medicine, targeted therapeutics, and the ever-expanding panorama of precision healthcare in the future. The combination of cutting-edge technology like AI with the inherent versatility of peptides opens the door to exceptional developments. The expanding peptide drugs narrative pains a captivating vision of a future in which these molecules continue to push the bounds of medical possibility, delivering innovative treatments and optimisms on the horizon.
Global Peptide Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2029 Reports Findings & Highlights:
- Global Peptide Therapeutics Market Opportunity: > USD 80 Billion By 2029
- Global & Regional Peptide Therapeutics Market Outlook
- Insight On Peptides In Clinical Trials By Country, Indication & Phase: > 900 Peptides In Trials
- Comprehensive Insight On Peptides Drugs Available in Market: > 200 Peptides
- Marketed Peptide Drugs Insight: Patent, Availability, Cost, Dosage, & Sales Insight
- Global, Regional, Annual & Quarterly Sales Insights
- Peptide Therapeutics Development Technologies Platform
- Global Peptide Drugs Clinical Research & Market Trends by Indication
Once overshadowed by small molecule and large protein based therapeutics, peptides have emerged as the new growth frontier of the pharmaceutical realm in the recent years. They have demonstrated therapeutic, diagnostic and theranostic properties, ushering in a new era of precision medicine. These adaptable molecules serve a critical role in treating a wide range of medical conditions by providing targeted therapeutic interventions. Beyond their treatment prowess, peptides illuminate the diagnostic landscape, serving as beacons in the detection of specific biomarkers and diseases. The convergence of therapeutic and diagnostic capabilities gives rise to the evolutionary concept of theranostics, where peptides act as both healers and guides, navigating the path toward personalized and effective healthcare solutions.
The continuous evolution of peptide drug development is fuelled by advancements in research and technology. Combinatorial chemistry and high-throughput screening have aided in the discovery of new peptide sequences with medicinal promise. Furthermore, advances in peptide synthesis processes have increased manufacturing efficiency, addressing historical issues with scalability and cost-effectiveness. The integration of computational tools and structure biology in peptide design has sped up the identification of lead compounds, reducing the time required for drug development.
The incorporation of artificial intelligence in peptide drug development has ushered in a new era of efficiency and innovation. Machine learning algorithms analyze vast datasets, predicting peptide structures with high binding affinities and enhancing the success rate of drug candidates. Additionally, AI helps in the identification of potential adverse events and optimization of pharmacokinetic properties, contributing to the overall quality of peptide therapeutics. Pharmaceutical companies such as ProteinQure have developed an extensive portfolio of peptide therapeutics using computational tools, while others like Space Peptides provide contract services to grant access to their machine learning and AI tools to design and produce premium peptide drugs.
The escalating interest of large pharmaceutical companies in peptide drugs is evident from the rapidly expanding global pipeline of peptide therapeutics. In addition, a surge of collaborations and strategic partnerships has been observed in the recent months within the pharmaceutical industry, some of these involving prominent pharmaceutical companies including Eli Lilly and AstraZeneca. Recognizing the potential of peptides to address unmet medical needs, prominent companies are aggressively seeking to expand their peptide portfolios through joint ventures, licensing agreements and acquisitions, which allow resource pooling and utilization of combined knowledge, thereby accelerating the development and commercialization of peptide drugs.
Peptide drugs are expected to play a significant role in the future landscape of the global pharmaceutical market. The growing understanding of disease causes at molecular levels coincides with the precision targeting abilities of peptides, making them a cornerstone in personalized medicine. Continuous advances in peptide engineering, together with the incorporation of AI, will almost certainly result in the development of highly effective and well-tolerated treatments. As the pharmaceutical industry move toward patient-centric paradigm, the adaptability and specificity of peptide drugs positions them as frontrunners in addressing the shifting healthcare landscape. Peptides’ adaptability across therapeutic areas, paired with their good safety rating, makes them an appealing choice for pharmaceutical companies seeking to fulfil patients’ medical diverse needs.
In conclusion, the journey through the realm of peptide drugs reveals an extensive array of innovation and potential. As we approach a new era in pharmaceuticals, peptides appear as more than merely therapeutic and diagnostic agents, but also as forerunners of a paradigm shift in healthcare. Peptides will play a crucial role in personalized medicine, targeted therapeutics, and the ever-expanding panorama of precision healthcare in the future. The combination of cutting-edge technology like AI with the inherent versatility of peptides opens the door to exceptional developments. The expanding peptide drugs narrative pains a captivating vision of a future in which these molecules continue to push the bounds of medical possibility, delivering innovative treatments and optimisms on the horizon.
1. INTRODUCTION TO PEPTIDE DRUGS
1.1 History, Development & Evolution
1.2 Approved Peptide Drugs
2. PEPTIDE DRUGS – THERAPEUTIC, DIAGNOSTIC & THERANOSTIC POTENTIAL & MARKET IMPLICATIONS
2.1 Therapeutic Potential & Market Implications
2.2 Diagnostic Potential & Market Implications
2.3 Theranostic Potential & Market Implications
3. GLOBAL PEPTIDE DRUGS CLINICAL RESEARCH & MARKET TRENDS BY INDICATION
3.1 Inheritable Genetic Diseases
3.2 Cancer
3.3 Microbial Infections
3.4 Autoimmune Disorders
3.5 Metabolic Disorders
3.6 Neurodegenerative Diseases
4. PEPTIDE BASED THERAPEUTIC APPROACHES
4.1 Peptide Hormone Drugs
4.2 Peptide Drug Conjugates
4.3 Peptide Vaccines
4.4 Peptide Agonists
4.5 Peptide Aptamers
4.6 Peptide Antibody
5. GLOBAL PEPTIDE THERAPEUTICS MARKET OUTLOOK
5.1 Current Market Trends & Drivers
5.2 Future Growth Avenues
6. PEPTIDE THERAPEUTICS MARKET LANDSCAPE BY REGION
6.1 US
6.2 EU
6.3 China
6.4 Japan
6.5 South Korea
6.6 UK
6.7 India
6.8 Middle East
6.9 Canada
6.10 Australia
7. GLOBAL PEPTIDE THERAPEUTICS CLINICAL TRIALS OVERVIEW
7.1 By Country
7.2 Indication
7.3 Phase
7.4 Priority Status
7.5 Therapy Class
8. MARKETED PEPTIDE DRUGS INSIGHT – PATENT, AVAILABILITY, COST, DOSAGE, & SALES INSIGHT
8.1 Bylvay
8.1.1 Overview
8.1.2 Pricing & Dosage Analysis
8.1.3 Sales Insight
8.2 Parsabiv
8.2.1 Overview & PatentS Insight
8.2.2 Pricing & Dosage Analysis
8.2.3 Sales Insight
8.3 Bydureon BCise
8.3.1 Overview & Patent Insight
8.3.2 Pricing & Dosage Analysis
8.3.3 Sales Insight
8.4 Linzess
8.4.1 Overview & Patent Insight
8.4.2 Pricing & Dosage Insight
8.4.3 Sales Insight
8.5 Increlex
8.5.1 Overview & Patent Insight
8.5.2 Pricing & Dosage Insight
8.5.3 Sales Analysis
8.6 Terlivaz
8.6.1 Overview & Patent Insight
8.6.2 Pricing & Dosage Insight
8.6.3 Sales Analysis
8.7 Empaveli
8.7.1 Overview & Patent Insight
8.7.2 Pricing & Dosage Insight
8.7.3 Sales Analysis
8.8 Voxzogo
8.8.1 Overview & Patent Insight
8.8.2 Pricing & Dosage Insight
8.8.3 Sales Analysis
8.9 Imcivree
8.9.1 Overview & Patent Insight
8.9.2 Pricing & Dosage Insight
8.9.3 Sales Analysis
8.10 Trulicity
8.10.1 Overview & Patent Insight
8.10.2 Pricing & Dosage Insight
8.10.3 Sales Analysis
8.11 Ozempic
8.11.1 Overview & Patent Insight
8.11.2 Pricing & Dosage Insight
8.11.3 Sales Analysis
8.12 Wegovy
8.12.1 Overview & Patent Insight
8.12.2 Pricing & Dosage Insight
8.12.3 Sales Analysis
8.13 Tresiba
8.13.1 Overview & Patent Insight
8.13.2 Pricing & Dosage Insight
8.13.3 Sales Analysis
8.14 Rybelsus
8.14.1 Overview & Patent Insight
8.14.2 Pricing & Dosage Insight
8.14.3 Sales Analysis
8.15 Xultophy
8.15.1 Overview & Patent Insight
8.15.2 Pricing & Dosage Insight
8.15.3 Sales Analysis
8.16 Victoza
8.16.1 Overview & Patent Insight
8.16.2 Pricing & Dosage Insight
8.16.3 Sales Analysis
8.17 Ryzodeg
8.17.1 Overview & Patent Insight
8.17.2 Pricing & Dosage Insight
8.17.3 Sales Analysis
8.18 Fiasp
8.18.1 Overview & Patent Insight
8.18.2 Pricing & Dosage Insight
8.18.3 Sales Analysis
8.19 Lantus
8.19.1 Overview & Patent Insight
8.19.2 Pricing & Dosage Insight
8.19.3 Sales Analysis
8.20 Toujeo
8.20.1 Overview & Patent Insight
8.20.2 Pricing & Dosage Insight
8.20.3 Sales Analysis
9. PEPTIDE THERAPEUTICS DEVELOPMENT TECHNOLOGIES PLATFORM
9.1 Biodrug Design Accelerator - Fujitsu/PeptiDream
9.2 T-Win® Technology - IO Biotech
9.3 Numatech – Numaferm
9.4 ProteinStudio – ProteinQure
9.5 The Magnifier N??™ - Nuritas
9.6 PepPower – GenScript
9.7 Unnamed Peptide Platform - Zealand Pharma
9.8 PDPS (Peptide Discovery Platform System) - PeptiDream
9.9 Veneno Suite - Veneno Technologies
9.10 SmartDepot™ Technology - Peptron
9.11 Bicycles - Bicycle Therapeutics
9.12 RALA Technolgy - pHion Therapeutics
9.13 Discovery Platform - Orbit Discovery
9.14 Imotopes – Imcyse
9.15 Nautilus - Peptilogics
9.16 Swarm Intelligence 2.0 – Pepticom
9.17 streaMLine Platform – Gubra
9.18 Precision Endocrine Peptides (PEPs) - MBX Biosciences
9.19 pHLIP (pH-Low Insertion Peptides) - pHLIP
9.20 alphalex – Cybrexa
10. CYCLIC PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-II/III
10.7 Phase-III
10.8 Preregistration
10.9 Registered
10.10 Marketed
11. PEPTIDE HORMONES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.5 Phase-I/II
11.6 Phase-II
11.7 Phase-II/III
11.8 Phase-III
11.9 Preregistration
11.10 Registered
11.11 Marketed
12. PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
12.1 Research
12.2 Preclinical
12.3 Phase-I
12.4 Phase-I/II
12.5 Phase-II
12.6 Phase-II/III
12.7 Phase-III
12.8 Preregistration
12.9 Registered
12.10 Marketed
13. GLUCAGON-LIKE PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
13.1 Preclinical
13.2 Phase-I
13.3 Phase-I/II
13.4 Phase-II
13.5 Phase-III
13.6 Marketed
14. OLIGOPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
14.1 Research
14.2 Preclinical
14.3 Phase-I
14.4 Phase-I/II
14.5 Phase-II
14.6 Phase-II/III
14.7 Phase-III
14.8 Registered
14.9 Marketed
15. LIPOPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
15.1 Research
15.2 Preclinical
15.3 Phase-II
15.4 Marketed
16. DIPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
16.1 Research
16.2 Preclinical
16.3 Phase-I
16.4 Phase-II
16.5 Phase-III
16.6 Registered
16.7 Marketed
17. DEPSIPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
17.1 Preclinical
17.2 Phase-I
17.3 Phase-II
17.4 Marketed
18. GLYCOPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
18.1 Preclinical
18.2 Phase-I
18.3 Phase-I/II
18.5 Phase-II
18.6 Phase-III
18.8 Marketed
19. PEPTIDE VACCINES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
19.1 Preclinical
19.2 Phase-I/II
19.3 Phase-II
19.4 Phase-III
19.5 Registered
19.6 Marketed
20. PEPTIDE FRAGMENTS CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
20.1 Preclinical
20.2 Phase-I
20.3 Phase-II
20.4 Phase-III
20.5 Preregistration
20.6 Registered
20.7 Marketed
21. OPIOID PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
21.1 Research
21.2 Preclinical
21.3 Phase-I
21.4 Phase-II
21.5 Preregistration
21.6 Registered
21.7 Marketed
22. NATRIURETIC PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
22.1 Preclinical
22.2 Phase-I
22.3 Phase-II
22.4 Phase-II/III
22.5 Phase-III
22.6 Marketed
23. NEUROPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
23.1 Research
23.2 Preclinical
23.3 Phase-I
23.4 Phase-I/II
23.5 Phase-II
23.6 Marketed
24. ANTIMICROBIAL CATIONIC PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
24.1 Preclinical
24.2 Phase-I
24.3 Phase-III
25. PEPTIDE HYDROLASES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
25.1 Phase-II
26. PEPTIDE APTAMERS
26.1 Research
26.2 Preclinical
26.3 Phase-I
26.4 Phase-II
27. INTERCELLULAR SIGNALLING PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
27.1 Phase-II
28. PEPTIDE ANTIBIOTICS CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
28.1 Phase-I
29. PEPTIDE DRUG CONJUGATES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
29.1 Preclinical
30. BICYCLIC PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
30.1 Preclinical
31. MULTIPLE PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
31.1 Research
31.2 Preclinical
31.3 Phase-I
31.4 Phase-I/II
31.5 Phase-II
31.6 Preregistration
31.7 Registered
31.8 Marketed
32. COMPETITIVE LANDSCAPE
32.1 AbbVie
32.2 Adocia
32.3 Amgen
32.4 Antlia Bioscience
32.5 AsclepiX Therapeutics
32.6 AstraZeneca
32.7 Bicycle Therapeutics
32.8 Biohaven Labs
32.9 Bristol-Myers Squibb
32.10 Carmot Therapeutics
32.11 Eli Lilly and Company
32.12 Ferring Pharmaceuticals
32.13 Gan&Lee Pharmaceuticals
32.14 GEROPHARM
32.15 Hanmi Pharmaceutical
32.16 HEC Pharm
32.17 Heidelberg Pharma AG
32.18 ImCyse
32.19 Janux Therapeutics
32.20 Kine Sciences
32.21 Lactocore
32.22 Maxwell Biosciences
32.23 Merck & Co
32.24 Novartis
32.25 Novo Nordisk
32.26 Oryn Therapeutics
32.27 Palatin Technologies
32.28 PeptiDream
32.29 Pfizer
32.30 Priavoid
32.31 Primary Peptides
32.32 Protagonist Therapeutics
32.33 Roche
32.34 Sanofi
32.35 Sapience Therapeutics
32.36 Seagen
32.37 Shaanxi Micot Technology Co
32.38 Stuart Therapeutics
32.39 Takeda
32.40 Zealand Pharma
12. LIST OF FIGURES
Figure 1-1: Landmarks in Peptides Drugs Market
Figure 3-1: Pro00013585 Phase II Study – Initiation & Completion Years
Figure 3-2: STUDY0000567 Phase II Study – Initiation & Completion Years
Figure 3-3: NCT05378672 Phase III Study – Initiation & Completion Years
Figure 3-4: ZP4207-21052 Phase III Study – Initiation & Completion Years
Figure 3-5: GLSI-21-01 Phase III Study – Initiation & Completion Years
Figure 3-6: IO102-IO103-013 Phase III Study – Initiation & Completion Years
Figure 3-7: NCT06091748 Phase II Study – Initiation & Completion Years
Figure 3-8: PMC67199 Phase I Study – Initiation & Completion Years
Figure 3-9: ACW-1221958-1 Phase II Study – Initiation & Completion Years
Figure 3-10: NCT05841095 Phase I/II Study – Initiation & Completion Years
Figure 3-11: NCT05340790 Phase I Study – Initiation & Completion Years
Figure 3-12: IR902-007 Phase I Study – Initiation & Completion Years
Figure 3-13: ISEMIS Phase I/II Study – Initiation & Completion Years
Figure 3-14: YN011-301 Phase II/III Study – Initiation & Completion Years
Figure 3-15: SCW0502-1031 Phase III Study – Initiation & Completion Years
Figure 3-16: NCT05202353 Phase I Study – Initiation & Completion Years
Figure 3-17: NCT04305002 Phase II Study – Initiation & Completion Years
Figure 3-18: NCT05189210 Phase II Study – Initiation & Completion Years
Figure 3-19: ALZ-C-001 Phase II Study – Initiation & Completion Years
Figure 3-20: ELViS-FA Phase I/II Study – Initiation & Completion Years
Figure 3-21: NCT05634876 Phase II Study – Initiation & Completion Years
Figure 4-1: CUV104 Phase II Study – Initiation & Completion Years
Figure 4-2: CUV152 Phase II Study – Initiation & Completion Years
Figure 4-3: Peptide-Drug Conjugate Structure
Figure 4-4: NCT04706962 Phase I Study – Initiation & Completion Years
Figure 4-5: MLB-PK-001 Early Phase I Study – Initiation & Completion Year
Figure 4-6: ANGLeD Phase III Study – Initiation & Completion Years
Figure 4-7: CA209-8TX Phase I/II Study – Initiation & Completion Years
Figure 4-8: CLAUDE/EOCRC1-22 Phase II Study – Initiation & Completion Years
Figure 4-9: COVENANT Phase III Study – Initiation & Completion Years
Figure 4-10: EGRABIS1 Phase II Study – Initiation & Completion Years
Figure 4-11: GLIMP Phase II Study – Initiation & Completion Years
Figure 4-12: NCT05530577 Phase II Study – Initiation & Completion Years
Figure 5-1: Global – Peptide Therapeutic Market Size (US$ Billion), 2022 - 2029
Figure 5-2: Global – Peptide Oncology Drugs Market Size (US$ Billion), 2022 - 2029
Figure 5-3: Ongoing Trends in Peptide Drugs Market
Figure 5-4: Future Growth Avenues in Peptide Drugs Market
Figure 6-1: China – Estimated Diabetes Population (Million), 2021 & 2030
Figure 6-2: India – Estimated Diabetes Population (Million), 2021 & 2030
Figure 6-3: ME – Estimated Diabetes Population in Saudi Arabia & UAE (Million), 2021
& 2030
Figure 6-4: Canada – Estimated Diabetes Population (Million), 2021 & 2030
Figure 7-1: Global - Peptides Clinical Trials by Country (Numbers), 2023 Till 2029
Figure 7-2: Global - Peptides Clinical Trials by Indication (Numbers), 2023 Till 2029
Figure 7-3: Global – Peptide Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-4: Global – Cyclic Peptide Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-5: Global – Peptide Hormones Clinical Trials by Phase (Numbers), 2023 till
2029
Figure 7-6: Global – Glucagon-Like Peptides Clinical Trials by Phase (Numbers), 2023
till 2029
Figure 7-7: Global – Oligopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-8: Global – Lipopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-9: Global – Dipeptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-10: Global – Depsipeptides Clinical Trials by Phase (Numbers), 2023 till
2029
Figure 7-11: Global – Glycopeptides Clinical Trials by Phase (Numbers), 2023 till
2029
Figure 7-12: Global – Peptide Vaccines Clinical Trials by Phase (Numbers), 2023 till
2029
Figure 7-13: Global – Peptide Fragments Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-14: Global – Opioid Peptides Clinical Trials by Phase (Numbers), 2023 till
2029
Figure 7-15: Global – Natriuretic Peptides Clinical Trials by Phase (Numbers), 2023
till 2029
Figure 7-16: Global – Neuropeptides Clinical Trials by Phase (Numbers), 2023 till
2029
Figure 7-17: Global – Antimicrobial Cationic Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-18: Global – Peptide Aptamers Clinical Trials by Phase (Numbers), 2023 till
2029
Figure 7-19: Global - Peptides Clinical Trials by Priority Status (Numbers), 2023 Till
2029
Figure 7-20: Global - Peptides Clinical Trials by Therapy Class (Numbers), 2023 Till
2029
Figure 8-1: US – Cost per Unit & Supply of Bylvay Oral Capsules (US$), November’2023
Figure 8-2: US – Cost per Unit & Supply of Bylvay Oral Pellets (US$), November’2023
Figure 8-3: EU – Cost per Unit & Supply of Bylvay Oral Capsules & Pellets (Eur/US$),
November’2023
Figure 8-4: Global – Quarterly Bylvay Sales (US$ Million), 2023
Figure 8-5: NA – Quarterly Bylvay Sales (US$ Million), 2023
Figure 8-6: Europe – Quarterly Bylvay Sales (US$ Million), 2023
Figure 8-7: ROW – Quarterly Bylvay Sales (US$ Million), 2023
Figure 8-8: Parsabiv – US Patents Expiration Years
Figure 8-9: Parsabiv – Europe Patents Expiration Years
Figure 8-10: Parsabiv – Cost per Unit & Supply (US$), November’2023
Figure 8-11: Global – Annual Parsabiv Sales (US$ Million), 2019-2023
Figure 8-12: US – Annual Parsabiv Sales (US$ Million), 2019-2023
Figure 8-13: ROW – Annual Parsabiv Sales (US$ Million), 2019-2023
Figure 8-14: Global – Quarterly Parsabiv Sales (US$ Million), 2023
Figure 8-15: US – Quarterly Parsabiv Sales (US$ Million), 2023
Figure 8-16: ROW – Quarterly Parsabiv Sales (US$ Million), 2023
Figure 8-17: Global – Quarterly Parsabiv Sales (US$ Million), 2022
Figure 8-18: US – Quarterly Parsabiv Sales (US$ Million), 2022
Figure 8-19: ROW – Quarterly Parsabiv Sales (US$ Million), 2022
Figure 8-20: Bydureon – Year of Approval and Expiry of Patents for Injection
Figure 8-21: Bydureon – Year of Approval and Expiry of Patents for Injection
Figure 8-22: Bydureon BCise – Cost per Unit & Supply (US$), November’2023
Figure 8-23: Global – Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-24: US – Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-25: Europe – Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-26: EM – Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-27: ROW – Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-28: Global – Quarterly Bydureon Sales (US$ Million), 2023
Figure 8-29: US – Quarterly Bydureon Sales (US$ Million), 2023
Figure 8-30: Europe – Quarterly Bydureon Sales (US$ Million), 2023
Figure 8-31: EM – Quarterly Bydureon Sales (US$ Million), 2023
Figure 8-32: Global – Quarterly Bydureon Sales (US$ Million), 2022
Figure 8-33: US – Quarterly Bydureon Sales (US$ Million), 2022
Figure 8-34: Europe – Quarterly Bydureon Sales (US$ Million), 2022
Figure 8-35: EM – Quarterly Bydureon Sales (US$ Million), 2022
Figure 8-36: Linzess – Cost per Unit & Supply (US$), November’2023
Figure 8-37: Linzess – Dosage by Indication (mcg)
Figure 8-38: Global – Annual Linzess Sales (US$ Million), 2020-2023
Figure 8-39: US – Annual Linzess Sales (US$ Million), 2020-2023
Figure 8-40: ROW – Annual Linzess Sales (US$ Million), 2019-2023
Figure 8-41: Global – Quarterly Linzess Sales (US$ Million), 2023
Figure 8-42: US – Quarterly Linzess Sales (US$ Million), 2023
Figure 8-43: ROW – Quarterly Linzess Sales (US$ Million), 2023
Figure 8-44: Global – Quarterly Linzess Sales (US$ Million), 2022
Figure 8-45: US – Quarterly Linzess Sales (US$ Million), 2022
Figure 8-46: ROW – Quarterly Linzess Sales (US$ Million), 2022
Figure 8-47: Increlex – US & EU Patent Expiry Years
Figure 8-48: Increlex – Cost per Unit & Supply (US$), November’2023
Figure 8-49: Global – Annual Increlex Sales (US$ Million), 2019-2023
Figure 8-50: Global – Quarterly Increlex Sales (US$ Million), 2023
Figure 8-51: Global – Quarterly Increlex Sales (US$ Million), 2022
Figure 8-52 : Terlivaz - Dosing Chart
Figure 8-53: Global – Quarterly Terlivaz Sales (US$ Million), 2023
Figure 8-54: Empaveli – Cost per Unit & Supply (US$), November’2023
Figure 8-55: Empaveli – Cost of Monthly & Yearly Treatment (US$), November’2023
Figure 8-56: Global – Annual Empaveli Sales (US$ Million), 2021-2023
Figure 8-57: US – Annual Empaveli Sales (US$ Million), 2021-2023
Figure 8-58: ROW – Annual Empaveli Sales (US$ Million), 2021-2023
Figure 8-59: Global – Quarterly Increlex Sales (US$ Million), 2023
Figure 8-60: US – Quarterly Empaveli Sales (US$ Million), 2023
Figure 8-61: ROW – Quarterly Empaveli Sales (US$ Million), 2023
Figure 8-62: Global – Quarterly Increlex Sales (US$ Million), 2022
Figure 8-63: US – Annual Empaveli Sales (US$ Million), 2022
Figure 8-64: ROW – Annual Empaveli Sales (US$ Million), 2022
Figure 8-65: Voxzogo – Cost per Unit & Supply (US$), November’2023
Figure 8-66: Global – Annual Voxzogo Sales (US$ Million), 2021-2023
Figure 8-67: Global – Quarterly Voxzogo Sales (US$ Million), 2023
Figure 8-68: Global – Quarterly Voxzogo Sales (US$ Million), 2022
Figure 8-69: Global – Annual Imcivree Sales (US$ Million), 2021-2023
Figure 8-70: Global – Quarterly Imcivree Sales (US$ Million), 2023
Figure 8-71: Global – Quarterly Imcivree Sales (US$ Million), 2022
Figure 8-72: Voxzogo – Cost per Unit & Supply (US$), November’2023
Figure 8-73: Global – Annual Trulicity Sales (US$ Million), 2019-2023
Figure 8-74: Global – Quarterly Trulicity Sales (US$ Million), 2023
Figure 8-75: Global – Quarterly Trulicity Sales (US$ Million), 2022
Figure 8-76: Ozempic – Cost per Unit & Supply (US$), November’2023
Figure 8-77: Ozempic – Initiation and Increment Doses (mg/week)
Figure 8-78: Global – Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-79: NA – Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-80: EMEA – Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-81: China – Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-82: ROW – Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-83: Global – Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-84: NA – Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-85: EMEA – Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-86: China – Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-87: ROW – Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-88: Global – Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-89: NA – Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-90: EMEA – Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-91: China – Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-92: ROW – Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-93: Wegovy – Cost per Unit & Supply of 0.25mg, 0.5mg and 1mg Solutions
(US$), November’2023
Figure 8-94: Wegovy – Cost per Unit & Supply of 1.7mg, and 2.4mg Solutions (US$),
November’2023
Figure 8-95: Global – Annual Wegovy Sales (US$ Million), 2021-2023
Figure 8-96: NA – Annual Wegovy Sales (US$ Million), 2021-2023
Figure 8-97: EMEA – Annual Wegovy Sales (US$ Million), 2021-2023
Figure 8-98: Global – Quarterly Wegovy Sales (US$ Million), 2023
Figure 8-99: NA – Quarterly Wegovy Sales (US$ Million), 2023
Figure 8-100: EMEA – Quarterly Wegovy Sales (US$ Million), 2023
Figure 8-101: Global – Quarterly Wegovy Sales (US$ Million), 2022
Figure 8-102: NA – Quarterly Wegovy Sales (US$ Million), 2022
Figure 8-103: EMEA – Quarterly Wegovy Sales (US$ Million), 2022
Figure 8-104: Tresiba – Cost per Unit & Supply of 100 units/mL Solution (US$),
November’2023
Figure 8-105: Tresiba – Cost per Unit & Supply of 200 units/mL Solution (US$),
November’2023
Figure 8-106: Insulin degludec – Cost per Unit & Supply of 100 units/mL Solution
(US$), November’2023
Figure 8-107: Global – Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-108: NA – Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-109: EMEA – Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-110: China – Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-111: ROW – Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-112: Global – Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-113: NA – Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-114: EMEA – Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-115: China – Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-116: ROW – Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-117: Global – Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-118: NA – Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-119: EMEA – Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-120: China – Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-121: ROW – Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-122: Rybelsus – Cost per Unit & Supply (US$), November’2023
Figure 8-123: Global – Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-124: NA – Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-125: EMEA – Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-126: China – Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-127: ROW – Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-128: Global – Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-129: NA – Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-130: EMEA – Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-131: China – Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-132: ROW – Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-133: Global – Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-134: NA – Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-135: EMEA – Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-136: China – Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-137: ROW – Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-138: Xultophy – Cost per Unit & Supply (US$), November’2023
Figure 8-139: Global – Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-140: NA – Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-141: EMEA – Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-142: China – Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-143: ROW – Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-144: Global – Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-145: NA – Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-146: EMEA – Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-147: China – Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-148: ROW – Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-149: Global – Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-150: NA – Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-151: EMEA – Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-152: China – Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-153: ROW – Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-154: Victoza – Cost per Unit & Supply (US$), November’2023
Figure 8-155: Global – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-156: North America – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-157: EMEA – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-158: China – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-159: ROW – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-160: Global – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-161: North America – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-162: EMEA – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-163: China – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-164: ROW – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-165: Global – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-166: North America – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-167: EMEA – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-168: China – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-169: ROW – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-170: Global – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-171: EMEA – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-172: China – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-173: ROW – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-174: Global – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-175: EMEA – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-176: China – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-177: ROW – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-178: Global – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-179: EMEA – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-180: China – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-181: ROW – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-182: Fiasp – Cost per Unit & Supply (US$), November’2023
Figure 8-183: Global – Annual Fiasp Sales (US$ Million), 2019-2023
Figure 8-184: NA – Annual Fiasp Sales (US$ Million), 2019-2023
Figure 8-185: EMEA – Annual Fiasp Sales (US$ Million), 2019-2023
Figure 8-186: ROW – Annual Fiasp Sales (US$ Million), 2019-2023
Figure 8-187: Global – Quarterly Fiasp Sales (US$ Million), 2023
Figure 8-188: NA – Quarterly Fiasp Sales (US$ Million), 2023
Figure 8-189: EMEA – Quarterly Fiasp Sales (US$ Million), 2023
Figure 8-190: ROW – Quarterly Fiasp Sales (US$ Million), 2023
Figure 8-191: Global – Quarterly Fiasp Sales (US$ Million), 2022
Figure 8-192: NA – Quarterly Fiasp Sales (US$ Million), 2022
Figure 8-193: EMEA – Quarterly Fiasp Sales (US$ Million), 2022
Figure 8-194: ROW – Quarterly Fiasp Sales (US$ Million), 2022
Figure 8-195: Lantus – Cost per Unit & Supply (US$), November’2023
Figure 8-196: Insulin Glargine & Insulin Glargine-yfgn – Cost per Unit & Supply (US$),
November’2023
Figure 8-197: Global – Annual Lantus Sales (US$ Million), 2019-2023
Figure 8-198: US – Annual Lantus Sales (US$ Million), 2019-2023
Figure 8-199: Europe – Annual Lantus Sales (US$ Million), 2019-2023
Figure 8-200: ROW – Annual Lantus Sales (US$ Million), 2019-2023
Figure 8-201: Global – Quarterly Lantus Sales (US$ Million), 2023
Figure 8-202: US – Quarterly Lantus Sales (US$ Million), 2023
Figure 8-203: Europe – Quarterly Lantus Sales (US$ Million), 2023
Figure 8-204: ROW – Quarterly Lantus Sales (US$ Million), 2023
Figure 8-205: Global – Quarterly Lantus Sales (US$ Million), 2022
Figure 8-206: US – Quarterly Lantus Sales (US$ Million), 2022
Figure 8-207: Europe – Quarterly Lantus Sales (US$ Million), 2022
Figure 8-208: ROW – Quarterly Lantus Sales (US$ Million), 2022
Figure 8-209: Toujeo – US Patent Acceptance & Expiration Years
Figure 8-210: Toujeo – Cost per Unit & Supply (US$), November’2023
Figure 8-211: Global – Annual Toujeo Sales (US$ Million), 2019-2023
Figure 8-212: US – Annual Toujeo Sales (US$ Million), 2019-2023
Figure 8-213: Europe – Annual Toujeo Sales (US$ Million), 2019-2023
Figure 8-214: ROW – Annual Toujeo Sales (US$ Million), 2019-2023
Figure 8-215: Global – Quarterly Toujeo Sales (US$ Million), 2023
Figure 8-216: US – Quarterly Toujeo Sales (US$ Million), 2023
Figure 8-217: Europe – Quarterly Toujeo Sales (US$ Million), 2023
Figure 8-218: ROW – Quarterly Toujeo Sales (US$ Million), 2023
Figure 8-219: Global – Quarterly Toujeo Sales (US$ Million), 2022
Figure 8-220: US – Quarterly Toujeo Sales (US$ Million), 2022
Figure 8-221: Europe – Quarterly Toujeo Sales (US$ Million), 2022
Figure 8-222: ROW – Quarterly Toujeo Sales (US$ Million), 2022
Figure 9-1: Biodrug Design Accelerator - Technical Benefits
Figure 9-2: Biodrug Design Accelerator - Technical Benefits
Figure 9-3: IO Biotech - T-win Technology
Figure 9-4: Numatech – Numaferm Platform
Figure 9-5: Nuritas - Scientific Achievements of Magnifier N?? Bioactive Peptide
Discovery Platform
Figure 9-6: Nuritas – The Magnifier N?? Bioactive Peptide Discovery Process
Figure 9-7: Nuritas – The Magnifier N?? Bioactive Peptide Results
Figure 9-8: GenScript - PepPower Technology
Figure 9-9: PeptiDream – PDPS Outline
Figure 9-10: PeptiDream – PDPS Outline
Figure 9-11: PeptiDream – PDPS Features
Figure 9-12: Benefits of DRPs as Drug Molecule Scaffold
Figure 9-13: Veneno Technologies - Veneno Suite Components
Figure 9-14: Veneno Technologies - Veneno Suite Process
Figure 9-15: Peptron - SmartDepot™ Features
Figure 9-16: Peptron - SmartDepot™ Manufacturing Scheme
Figure 9-17: Bicycle Therapeutics – Bicycles Key Properties
Figure 9-18: Bicycle Therapeutics – Bicycles Key Properties
Figure 9-19: pHion Therapeutics - RALA Nanoparticles Advantages
Figure 9-20: pHion Therapeutics - RALA Nanoparticles BENEFITS
Figure 9-21: Orbit Discovery - Orbit Peptide Display Engine
Figure 9-22: Benefits of Imotopes over Current Therapies
Figure 9-23: Peptilogics – Peptide Development Process
Figure 9-24: Peptilogics - Nautilus Features
Figure 9-25: Pepticom - Swarm Intelligence 2.0 AI platform
Figure 9-26: Cybrexa – alphalex Selective Tumor Cell Targeting
12. LIST OF TABLES
Table 1- 1: Landmarks in Peptides Drugs Market
Table 6-1: US - Recent FDA Designations for Peptide Drug Candidates
Table 8-1: Bylvay - Recommended Dosage for 40 mcg/kg/day
Table 8-2: Parsabiv - Recommended Schedule for Monitoring Corrected Serum
Calcium and Parathyroid Hormone Levels during Treatment
Table 8-3: Voxzogo - Recommended Daily Dosage and Injection Volume
Table 8-4: Wegovy - Recommended Dosage Regimen for Adults
Table 8-5: Wegovy - Recommended Dosage Regimen for Pediatric Patients Aged
Years and Older
Table 9-1: GenScript - PepPower™ Platform Advantages
1.1 History, Development & Evolution
1.2 Approved Peptide Drugs
2. PEPTIDE DRUGS – THERAPEUTIC, DIAGNOSTIC & THERANOSTIC POTENTIAL & MARKET IMPLICATIONS
2.1 Therapeutic Potential & Market Implications
2.2 Diagnostic Potential & Market Implications
2.3 Theranostic Potential & Market Implications
3. GLOBAL PEPTIDE DRUGS CLINICAL RESEARCH & MARKET TRENDS BY INDICATION
3.1 Inheritable Genetic Diseases
3.2 Cancer
3.3 Microbial Infections
3.4 Autoimmune Disorders
3.5 Metabolic Disorders
3.6 Neurodegenerative Diseases
4. PEPTIDE BASED THERAPEUTIC APPROACHES
4.1 Peptide Hormone Drugs
4.2 Peptide Drug Conjugates
4.3 Peptide Vaccines
4.4 Peptide Agonists
4.5 Peptide Aptamers
4.6 Peptide Antibody
5. GLOBAL PEPTIDE THERAPEUTICS MARKET OUTLOOK
5.1 Current Market Trends & Drivers
5.2 Future Growth Avenues
6. PEPTIDE THERAPEUTICS MARKET LANDSCAPE BY REGION
6.1 US
6.2 EU
6.3 China
6.4 Japan
6.5 South Korea
6.6 UK
6.7 India
6.8 Middle East
6.9 Canada
6.10 Australia
7. GLOBAL PEPTIDE THERAPEUTICS CLINICAL TRIALS OVERVIEW
7.1 By Country
7.2 Indication
7.3 Phase
7.4 Priority Status
7.5 Therapy Class
8. MARKETED PEPTIDE DRUGS INSIGHT – PATENT, AVAILABILITY, COST, DOSAGE, & SALES INSIGHT
8.1 Bylvay
8.1.1 Overview
8.1.2 Pricing & Dosage Analysis
8.1.3 Sales Insight
8.2 Parsabiv
8.2.1 Overview & PatentS Insight
8.2.2 Pricing & Dosage Analysis
8.2.3 Sales Insight
8.3 Bydureon BCise
8.3.1 Overview & Patent Insight
8.3.2 Pricing & Dosage Analysis
8.3.3 Sales Insight
8.4 Linzess
8.4.1 Overview & Patent Insight
8.4.2 Pricing & Dosage Insight
8.4.3 Sales Insight
8.5 Increlex
8.5.1 Overview & Patent Insight
8.5.2 Pricing & Dosage Insight
8.5.3 Sales Analysis
8.6 Terlivaz
8.6.1 Overview & Patent Insight
8.6.2 Pricing & Dosage Insight
8.6.3 Sales Analysis
8.7 Empaveli
8.7.1 Overview & Patent Insight
8.7.2 Pricing & Dosage Insight
8.7.3 Sales Analysis
8.8 Voxzogo
8.8.1 Overview & Patent Insight
8.8.2 Pricing & Dosage Insight
8.8.3 Sales Analysis
8.9 Imcivree
8.9.1 Overview & Patent Insight
8.9.2 Pricing & Dosage Insight
8.9.3 Sales Analysis
8.10 Trulicity
8.10.1 Overview & Patent Insight
8.10.2 Pricing & Dosage Insight
8.10.3 Sales Analysis
8.11 Ozempic
8.11.1 Overview & Patent Insight
8.11.2 Pricing & Dosage Insight
8.11.3 Sales Analysis
8.12 Wegovy
8.12.1 Overview & Patent Insight
8.12.2 Pricing & Dosage Insight
8.12.3 Sales Analysis
8.13 Tresiba
8.13.1 Overview & Patent Insight
8.13.2 Pricing & Dosage Insight
8.13.3 Sales Analysis
8.14 Rybelsus
8.14.1 Overview & Patent Insight
8.14.2 Pricing & Dosage Insight
8.14.3 Sales Analysis
8.15 Xultophy
8.15.1 Overview & Patent Insight
8.15.2 Pricing & Dosage Insight
8.15.3 Sales Analysis
8.16 Victoza
8.16.1 Overview & Patent Insight
8.16.2 Pricing & Dosage Insight
8.16.3 Sales Analysis
8.17 Ryzodeg
8.17.1 Overview & Patent Insight
8.17.2 Pricing & Dosage Insight
8.17.3 Sales Analysis
8.18 Fiasp
8.18.1 Overview & Patent Insight
8.18.2 Pricing & Dosage Insight
8.18.3 Sales Analysis
8.19 Lantus
8.19.1 Overview & Patent Insight
8.19.2 Pricing & Dosage Insight
8.19.3 Sales Analysis
8.20 Toujeo
8.20.1 Overview & Patent Insight
8.20.2 Pricing & Dosage Insight
8.20.3 Sales Analysis
9. PEPTIDE THERAPEUTICS DEVELOPMENT TECHNOLOGIES PLATFORM
9.1 Biodrug Design Accelerator - Fujitsu/PeptiDream
9.2 T-Win® Technology - IO Biotech
9.3 Numatech – Numaferm
9.4 ProteinStudio – ProteinQure
9.5 The Magnifier N??™ - Nuritas
9.6 PepPower – GenScript
9.7 Unnamed Peptide Platform - Zealand Pharma
9.8 PDPS (Peptide Discovery Platform System) - PeptiDream
9.9 Veneno Suite - Veneno Technologies
9.10 SmartDepot™ Technology - Peptron
9.11 Bicycles - Bicycle Therapeutics
9.12 RALA Technolgy - pHion Therapeutics
9.13 Discovery Platform - Orbit Discovery
9.14 Imotopes – Imcyse
9.15 Nautilus - Peptilogics
9.16 Swarm Intelligence 2.0 – Pepticom
9.17 streaMLine Platform – Gubra
9.18 Precision Endocrine Peptides (PEPs) - MBX Biosciences
9.19 pHLIP (pH-Low Insertion Peptides) - pHLIP
9.20 alphalex – Cybrexa
10. CYCLIC PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-II/III
10.7 Phase-III
10.8 Preregistration
10.9 Registered
10.10 Marketed
11. PEPTIDE HORMONES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.5 Phase-I/II
11.6 Phase-II
11.7 Phase-II/III
11.8 Phase-III
11.9 Preregistration
11.10 Registered
11.11 Marketed
12. PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
12.1 Research
12.2 Preclinical
12.3 Phase-I
12.4 Phase-I/II
12.5 Phase-II
12.6 Phase-II/III
12.7 Phase-III
12.8 Preregistration
12.9 Registered
12.10 Marketed
13. GLUCAGON-LIKE PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
13.1 Preclinical
13.2 Phase-I
13.3 Phase-I/II
13.4 Phase-II
13.5 Phase-III
13.6 Marketed
14. OLIGOPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
14.1 Research
14.2 Preclinical
14.3 Phase-I
14.4 Phase-I/II
14.5 Phase-II
14.6 Phase-II/III
14.7 Phase-III
14.8 Registered
14.9 Marketed
15. LIPOPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
15.1 Research
15.2 Preclinical
15.3 Phase-II
15.4 Marketed
16. DIPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
16.1 Research
16.2 Preclinical
16.3 Phase-I
16.4 Phase-II
16.5 Phase-III
16.6 Registered
16.7 Marketed
17. DEPSIPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
17.1 Preclinical
17.2 Phase-I
17.3 Phase-II
17.4 Marketed
18. GLYCOPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
18.1 Preclinical
18.2 Phase-I
18.3 Phase-I/II
18.5 Phase-II
18.6 Phase-III
18.8 Marketed
19. PEPTIDE VACCINES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
19.1 Preclinical
19.2 Phase-I/II
19.3 Phase-II
19.4 Phase-III
19.5 Registered
19.6 Marketed
20. PEPTIDE FRAGMENTS CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
20.1 Preclinical
20.2 Phase-I
20.3 Phase-II
20.4 Phase-III
20.5 Preregistration
20.6 Registered
20.7 Marketed
21. OPIOID PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
21.1 Research
21.2 Preclinical
21.3 Phase-I
21.4 Phase-II
21.5 Preregistration
21.6 Registered
21.7 Marketed
22. NATRIURETIC PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
22.1 Preclinical
22.2 Phase-I
22.3 Phase-II
22.4 Phase-II/III
22.5 Phase-III
22.6 Marketed
23. NEUROPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
23.1 Research
23.2 Preclinical
23.3 Phase-I
23.4 Phase-I/II
23.5 Phase-II
23.6 Marketed
24. ANTIMICROBIAL CATIONIC PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
24.1 Preclinical
24.2 Phase-I
24.3 Phase-III
25. PEPTIDE HYDROLASES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
25.1 Phase-II
26. PEPTIDE APTAMERS
26.1 Research
26.2 Preclinical
26.3 Phase-I
26.4 Phase-II
27. INTERCELLULAR SIGNALLING PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
27.1 Phase-II
28. PEPTIDE ANTIBIOTICS CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
28.1 Phase-I
29. PEPTIDE DRUG CONJUGATES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
29.1 Preclinical
30. BICYCLIC PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
30.1 Preclinical
31. MULTIPLE PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE
31.1 Research
31.2 Preclinical
31.3 Phase-I
31.4 Phase-I/II
31.5 Phase-II
31.6 Preregistration
31.7 Registered
31.8 Marketed
32. COMPETITIVE LANDSCAPE
32.1 AbbVie
32.2 Adocia
32.3 Amgen
32.4 Antlia Bioscience
32.5 AsclepiX Therapeutics
32.6 AstraZeneca
32.7 Bicycle Therapeutics
32.8 Biohaven Labs
32.9 Bristol-Myers Squibb
32.10 Carmot Therapeutics
32.11 Eli Lilly and Company
32.12 Ferring Pharmaceuticals
32.13 Gan&Lee Pharmaceuticals
32.14 GEROPHARM
32.15 Hanmi Pharmaceutical
32.16 HEC Pharm
32.17 Heidelberg Pharma AG
32.18 ImCyse
32.19 Janux Therapeutics
32.20 Kine Sciences
32.21 Lactocore
32.22 Maxwell Biosciences
32.23 Merck & Co
32.24 Novartis
32.25 Novo Nordisk
32.26 Oryn Therapeutics
32.27 Palatin Technologies
32.28 PeptiDream
32.29 Pfizer
32.30 Priavoid
32.31 Primary Peptides
32.32 Protagonist Therapeutics
32.33 Roche
32.34 Sanofi
32.35 Sapience Therapeutics
32.36 Seagen
32.37 Shaanxi Micot Technology Co
32.38 Stuart Therapeutics
32.39 Takeda
32.40 Zealand Pharma
12. LIST OF FIGURES
Figure 1-1: Landmarks in Peptides Drugs Market
Figure 3-1: Pro00013585 Phase II Study – Initiation & Completion Years
Figure 3-2: STUDY0000567 Phase II Study – Initiation & Completion Years
Figure 3-3: NCT05378672 Phase III Study – Initiation & Completion Years
Figure 3-4: ZP4207-21052 Phase III Study – Initiation & Completion Years
Figure 3-5: GLSI-21-01 Phase III Study – Initiation & Completion Years
Figure 3-6: IO102-IO103-013 Phase III Study – Initiation & Completion Years
Figure 3-7: NCT06091748 Phase II Study – Initiation & Completion Years
Figure 3-8: PMC67199 Phase I Study – Initiation & Completion Years
Figure 3-9: ACW-1221958-1 Phase II Study – Initiation & Completion Years
Figure 3-10: NCT05841095 Phase I/II Study – Initiation & Completion Years
Figure 3-11: NCT05340790 Phase I Study – Initiation & Completion Years
Figure 3-12: IR902-007 Phase I Study – Initiation & Completion Years
Figure 3-13: ISEMIS Phase I/II Study – Initiation & Completion Years
Figure 3-14: YN011-301 Phase II/III Study – Initiation & Completion Years
Figure 3-15: SCW0502-1031 Phase III Study – Initiation & Completion Years
Figure 3-16: NCT05202353 Phase I Study – Initiation & Completion Years
Figure 3-17: NCT04305002 Phase II Study – Initiation & Completion Years
Figure 3-18: NCT05189210 Phase II Study – Initiation & Completion Years
Figure 3-19: ALZ-C-001 Phase II Study – Initiation & Completion Years
Figure 3-20: ELViS-FA Phase I/II Study – Initiation & Completion Years
Figure 3-21: NCT05634876 Phase II Study – Initiation & Completion Years
Figure 4-1: CUV104 Phase II Study – Initiation & Completion Years
Figure 4-2: CUV152 Phase II Study – Initiation & Completion Years
Figure 4-3: Peptide-Drug Conjugate Structure
Figure 4-4: NCT04706962 Phase I Study – Initiation & Completion Years
Figure 4-5: MLB-PK-001 Early Phase I Study – Initiation & Completion Year
Figure 4-6: ANGLeD Phase III Study – Initiation & Completion Years
Figure 4-7: CA209-8TX Phase I/II Study – Initiation & Completion Years
Figure 4-8: CLAUDE/EOCRC1-22 Phase II Study – Initiation & Completion Years
Figure 4-9: COVENANT Phase III Study – Initiation & Completion Years
Figure 4-10: EGRABIS1 Phase II Study – Initiation & Completion Years
Figure 4-11: GLIMP Phase II Study – Initiation & Completion Years
Figure 4-12: NCT05530577 Phase II Study – Initiation & Completion Years
Figure 5-1: Global – Peptide Therapeutic Market Size (US$ Billion), 2022 - 2029
Figure 5-2: Global – Peptide Oncology Drugs Market Size (US$ Billion), 2022 - 2029
Figure 5-3: Ongoing Trends in Peptide Drugs Market
Figure 5-4: Future Growth Avenues in Peptide Drugs Market
Figure 6-1: China – Estimated Diabetes Population (Million), 2021 & 2030
Figure 6-2: India – Estimated Diabetes Population (Million), 2021 & 2030
Figure 6-3: ME – Estimated Diabetes Population in Saudi Arabia & UAE (Million), 2021
& 2030
Figure 6-4: Canada – Estimated Diabetes Population (Million), 2021 & 2030
Figure 7-1: Global - Peptides Clinical Trials by Country (Numbers), 2023 Till 2029
Figure 7-2: Global - Peptides Clinical Trials by Indication (Numbers), 2023 Till 2029
Figure 7-3: Global – Peptide Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-4: Global – Cyclic Peptide Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-5: Global – Peptide Hormones Clinical Trials by Phase (Numbers), 2023 till
2029
Figure 7-6: Global – Glucagon-Like Peptides Clinical Trials by Phase (Numbers), 2023
till 2029
Figure 7-7: Global – Oligopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-8: Global – Lipopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-9: Global – Dipeptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-10: Global – Depsipeptides Clinical Trials by Phase (Numbers), 2023 till
2029
Figure 7-11: Global – Glycopeptides Clinical Trials by Phase (Numbers), 2023 till
2029
Figure 7-12: Global – Peptide Vaccines Clinical Trials by Phase (Numbers), 2023 till
2029
Figure 7-13: Global – Peptide Fragments Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-14: Global – Opioid Peptides Clinical Trials by Phase (Numbers), 2023 till
2029
Figure 7-15: Global – Natriuretic Peptides Clinical Trials by Phase (Numbers), 2023
till 2029
Figure 7-16: Global – Neuropeptides Clinical Trials by Phase (Numbers), 2023 till
2029
Figure 7-17: Global – Antimicrobial Cationic Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-18: Global – Peptide Aptamers Clinical Trials by Phase (Numbers), 2023 till
2029
Figure 7-19: Global - Peptides Clinical Trials by Priority Status (Numbers), 2023 Till
2029
Figure 7-20: Global - Peptides Clinical Trials by Therapy Class (Numbers), 2023 Till
2029
Figure 8-1: US – Cost per Unit & Supply of Bylvay Oral Capsules (US$), November’2023
Figure 8-2: US – Cost per Unit & Supply of Bylvay Oral Pellets (US$), November’2023
Figure 8-3: EU – Cost per Unit & Supply of Bylvay Oral Capsules & Pellets (Eur/US$),
November’2023
Figure 8-4: Global – Quarterly Bylvay Sales (US$ Million), 2023
Figure 8-5: NA – Quarterly Bylvay Sales (US$ Million), 2023
Figure 8-6: Europe – Quarterly Bylvay Sales (US$ Million), 2023
Figure 8-7: ROW – Quarterly Bylvay Sales (US$ Million), 2023
Figure 8-8: Parsabiv – US Patents Expiration Years
Figure 8-9: Parsabiv – Europe Patents Expiration Years
Figure 8-10: Parsabiv – Cost per Unit & Supply (US$), November’2023
Figure 8-11: Global – Annual Parsabiv Sales (US$ Million), 2019-2023
Figure 8-12: US – Annual Parsabiv Sales (US$ Million), 2019-2023
Figure 8-13: ROW – Annual Parsabiv Sales (US$ Million), 2019-2023
Figure 8-14: Global – Quarterly Parsabiv Sales (US$ Million), 2023
Figure 8-15: US – Quarterly Parsabiv Sales (US$ Million), 2023
Figure 8-16: ROW – Quarterly Parsabiv Sales (US$ Million), 2023
Figure 8-17: Global – Quarterly Parsabiv Sales (US$ Million), 2022
Figure 8-18: US – Quarterly Parsabiv Sales (US$ Million), 2022
Figure 8-19: ROW – Quarterly Parsabiv Sales (US$ Million), 2022
Figure 8-20: Bydureon – Year of Approval and Expiry of Patents for Injection
Figure 8-21: Bydureon – Year of Approval and Expiry of Patents for Injection
Figure 8-22: Bydureon BCise – Cost per Unit & Supply (US$), November’2023
Figure 8-23: Global – Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-24: US – Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-25: Europe – Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-26: EM – Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-27: ROW – Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-28: Global – Quarterly Bydureon Sales (US$ Million), 2023
Figure 8-29: US – Quarterly Bydureon Sales (US$ Million), 2023
Figure 8-30: Europe – Quarterly Bydureon Sales (US$ Million), 2023
Figure 8-31: EM – Quarterly Bydureon Sales (US$ Million), 2023
Figure 8-32: Global – Quarterly Bydureon Sales (US$ Million), 2022
Figure 8-33: US – Quarterly Bydureon Sales (US$ Million), 2022
Figure 8-34: Europe – Quarterly Bydureon Sales (US$ Million), 2022
Figure 8-35: EM – Quarterly Bydureon Sales (US$ Million), 2022
Figure 8-36: Linzess – Cost per Unit & Supply (US$), November’2023
Figure 8-37: Linzess – Dosage by Indication (mcg)
Figure 8-38: Global – Annual Linzess Sales (US$ Million), 2020-2023
Figure 8-39: US – Annual Linzess Sales (US$ Million), 2020-2023
Figure 8-40: ROW – Annual Linzess Sales (US$ Million), 2019-2023
Figure 8-41: Global – Quarterly Linzess Sales (US$ Million), 2023
Figure 8-42: US – Quarterly Linzess Sales (US$ Million), 2023
Figure 8-43: ROW – Quarterly Linzess Sales (US$ Million), 2023
Figure 8-44: Global – Quarterly Linzess Sales (US$ Million), 2022
Figure 8-45: US – Quarterly Linzess Sales (US$ Million), 2022
Figure 8-46: ROW – Quarterly Linzess Sales (US$ Million), 2022
Figure 8-47: Increlex – US & EU Patent Expiry Years
Figure 8-48: Increlex – Cost per Unit & Supply (US$), November’2023
Figure 8-49: Global – Annual Increlex Sales (US$ Million), 2019-2023
Figure 8-50: Global – Quarterly Increlex Sales (US$ Million), 2023
Figure 8-51: Global – Quarterly Increlex Sales (US$ Million), 2022
Figure 8-52 : Terlivaz - Dosing Chart
Figure 8-53: Global – Quarterly Terlivaz Sales (US$ Million), 2023
Figure 8-54: Empaveli – Cost per Unit & Supply (US$), November’2023
Figure 8-55: Empaveli – Cost of Monthly & Yearly Treatment (US$), November’2023
Figure 8-56: Global – Annual Empaveli Sales (US$ Million), 2021-2023
Figure 8-57: US – Annual Empaveli Sales (US$ Million), 2021-2023
Figure 8-58: ROW – Annual Empaveli Sales (US$ Million), 2021-2023
Figure 8-59: Global – Quarterly Increlex Sales (US$ Million), 2023
Figure 8-60: US – Quarterly Empaveli Sales (US$ Million), 2023
Figure 8-61: ROW – Quarterly Empaveli Sales (US$ Million), 2023
Figure 8-62: Global – Quarterly Increlex Sales (US$ Million), 2022
Figure 8-63: US – Annual Empaveli Sales (US$ Million), 2022
Figure 8-64: ROW – Annual Empaveli Sales (US$ Million), 2022
Figure 8-65: Voxzogo – Cost per Unit & Supply (US$), November’2023
Figure 8-66: Global – Annual Voxzogo Sales (US$ Million), 2021-2023
Figure 8-67: Global – Quarterly Voxzogo Sales (US$ Million), 2023
Figure 8-68: Global – Quarterly Voxzogo Sales (US$ Million), 2022
Figure 8-69: Global – Annual Imcivree Sales (US$ Million), 2021-2023
Figure 8-70: Global – Quarterly Imcivree Sales (US$ Million), 2023
Figure 8-71: Global – Quarterly Imcivree Sales (US$ Million), 2022
Figure 8-72: Voxzogo – Cost per Unit & Supply (US$), November’2023
Figure 8-73: Global – Annual Trulicity Sales (US$ Million), 2019-2023
Figure 8-74: Global – Quarterly Trulicity Sales (US$ Million), 2023
Figure 8-75: Global – Quarterly Trulicity Sales (US$ Million), 2022
Figure 8-76: Ozempic – Cost per Unit & Supply (US$), November’2023
Figure 8-77: Ozempic – Initiation and Increment Doses (mg/week)
Figure 8-78: Global – Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-79: NA – Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-80: EMEA – Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-81: China – Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-82: ROW – Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-83: Global – Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-84: NA – Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-85: EMEA – Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-86: China – Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-87: ROW – Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-88: Global – Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-89: NA – Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-90: EMEA – Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-91: China – Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-92: ROW – Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-93: Wegovy – Cost per Unit & Supply of 0.25mg, 0.5mg and 1mg Solutions
(US$), November’2023
Figure 8-94: Wegovy – Cost per Unit & Supply of 1.7mg, and 2.4mg Solutions (US$),
November’2023
Figure 8-95: Global – Annual Wegovy Sales (US$ Million), 2021-2023
Figure 8-96: NA – Annual Wegovy Sales (US$ Million), 2021-2023
Figure 8-97: EMEA – Annual Wegovy Sales (US$ Million), 2021-2023
Figure 8-98: Global – Quarterly Wegovy Sales (US$ Million), 2023
Figure 8-99: NA – Quarterly Wegovy Sales (US$ Million), 2023
Figure 8-100: EMEA – Quarterly Wegovy Sales (US$ Million), 2023
Figure 8-101: Global – Quarterly Wegovy Sales (US$ Million), 2022
Figure 8-102: NA – Quarterly Wegovy Sales (US$ Million), 2022
Figure 8-103: EMEA – Quarterly Wegovy Sales (US$ Million), 2022
Figure 8-104: Tresiba – Cost per Unit & Supply of 100 units/mL Solution (US$),
November’2023
Figure 8-105: Tresiba – Cost per Unit & Supply of 200 units/mL Solution (US$),
November’2023
Figure 8-106: Insulin degludec – Cost per Unit & Supply of 100 units/mL Solution
(US$), November’2023
Figure 8-107: Global – Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-108: NA – Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-109: EMEA – Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-110: China – Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-111: ROW – Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-112: Global – Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-113: NA – Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-114: EMEA – Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-115: China – Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-116: ROW – Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-117: Global – Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-118: NA – Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-119: EMEA – Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-120: China – Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-121: ROW – Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-122: Rybelsus – Cost per Unit & Supply (US$), November’2023
Figure 8-123: Global – Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-124: NA – Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-125: EMEA – Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-126: China – Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-127: ROW – Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-128: Global – Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-129: NA – Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-130: EMEA – Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-131: China – Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-132: ROW – Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-133: Global – Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-134: NA – Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-135: EMEA – Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-136: China – Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-137: ROW – Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-138: Xultophy – Cost per Unit & Supply (US$), November’2023
Figure 8-139: Global – Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-140: NA – Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-141: EMEA – Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-142: China – Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-143: ROW – Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-144: Global – Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-145: NA – Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-146: EMEA – Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-147: China – Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-148: ROW – Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-149: Global – Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-150: NA – Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-151: EMEA – Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-152: China – Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-153: ROW – Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-154: Victoza – Cost per Unit & Supply (US$), November’2023
Figure 8-155: Global – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-156: North America – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-157: EMEA – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-158: China – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-159: ROW – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-160: Global – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-161: North America – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-162: EMEA – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-163: China – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-164: ROW – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-165: Global – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-166: North America – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-167: EMEA – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-168: China – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-169: ROW – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-170: Global – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-171: EMEA – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-172: China – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-173: ROW – Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-174: Global – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-175: EMEA – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-176: China – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-177: ROW – Quarterly Victoza Sales (US$ Million), 2023
Figure 8-178: Global – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-179: EMEA – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-180: China – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-181: ROW – Quarterly Victoza Sales (US$ Million), 2022
Figure 8-182: Fiasp – Cost per Unit & Supply (US$), November’2023
Figure 8-183: Global – Annual Fiasp Sales (US$ Million), 2019-2023
Figure 8-184: NA – Annual Fiasp Sales (US$ Million), 2019-2023
Figure 8-185: EMEA – Annual Fiasp Sales (US$ Million), 2019-2023
Figure 8-186: ROW – Annual Fiasp Sales (US$ Million), 2019-2023
Figure 8-187: Global – Quarterly Fiasp Sales (US$ Million), 2023
Figure 8-188: NA – Quarterly Fiasp Sales (US$ Million), 2023
Figure 8-189: EMEA – Quarterly Fiasp Sales (US$ Million), 2023
Figure 8-190: ROW – Quarterly Fiasp Sales (US$ Million), 2023
Figure 8-191: Global – Quarterly Fiasp Sales (US$ Million), 2022
Figure 8-192: NA – Quarterly Fiasp Sales (US$ Million), 2022
Figure 8-193: EMEA – Quarterly Fiasp Sales (US$ Million), 2022
Figure 8-194: ROW – Quarterly Fiasp Sales (US$ Million), 2022
Figure 8-195: Lantus – Cost per Unit & Supply (US$), November’2023
Figure 8-196: Insulin Glargine & Insulin Glargine-yfgn – Cost per Unit & Supply (US$),
November’2023
Figure 8-197: Global – Annual Lantus Sales (US$ Million), 2019-2023
Figure 8-198: US – Annual Lantus Sales (US$ Million), 2019-2023
Figure 8-199: Europe – Annual Lantus Sales (US$ Million), 2019-2023
Figure 8-200: ROW – Annual Lantus Sales (US$ Million), 2019-2023
Figure 8-201: Global – Quarterly Lantus Sales (US$ Million), 2023
Figure 8-202: US – Quarterly Lantus Sales (US$ Million), 2023
Figure 8-203: Europe – Quarterly Lantus Sales (US$ Million), 2023
Figure 8-204: ROW – Quarterly Lantus Sales (US$ Million), 2023
Figure 8-205: Global – Quarterly Lantus Sales (US$ Million), 2022
Figure 8-206: US – Quarterly Lantus Sales (US$ Million), 2022
Figure 8-207: Europe – Quarterly Lantus Sales (US$ Million), 2022
Figure 8-208: ROW – Quarterly Lantus Sales (US$ Million), 2022
Figure 8-209: Toujeo – US Patent Acceptance & Expiration Years
Figure 8-210: Toujeo – Cost per Unit & Supply (US$), November’2023
Figure 8-211: Global – Annual Toujeo Sales (US$ Million), 2019-2023
Figure 8-212: US – Annual Toujeo Sales (US$ Million), 2019-2023
Figure 8-213: Europe – Annual Toujeo Sales (US$ Million), 2019-2023
Figure 8-214: ROW – Annual Toujeo Sales (US$ Million), 2019-2023
Figure 8-215: Global – Quarterly Toujeo Sales (US$ Million), 2023
Figure 8-216: US – Quarterly Toujeo Sales (US$ Million), 2023
Figure 8-217: Europe – Quarterly Toujeo Sales (US$ Million), 2023
Figure 8-218: ROW – Quarterly Toujeo Sales (US$ Million), 2023
Figure 8-219: Global – Quarterly Toujeo Sales (US$ Million), 2022
Figure 8-220: US – Quarterly Toujeo Sales (US$ Million), 2022
Figure 8-221: Europe – Quarterly Toujeo Sales (US$ Million), 2022
Figure 8-222: ROW – Quarterly Toujeo Sales (US$ Million), 2022
Figure 9-1: Biodrug Design Accelerator - Technical Benefits
Figure 9-2: Biodrug Design Accelerator - Technical Benefits
Figure 9-3: IO Biotech - T-win Technology
Figure 9-4: Numatech – Numaferm Platform
Figure 9-5: Nuritas - Scientific Achievements of Magnifier N?? Bioactive Peptide
Discovery Platform
Figure 9-6: Nuritas – The Magnifier N?? Bioactive Peptide Discovery Process
Figure 9-7: Nuritas – The Magnifier N?? Bioactive Peptide Results
Figure 9-8: GenScript - PepPower Technology
Figure 9-9: PeptiDream – PDPS Outline
Figure 9-10: PeptiDream – PDPS Outline
Figure 9-11: PeptiDream – PDPS Features
Figure 9-12: Benefits of DRPs as Drug Molecule Scaffold
Figure 9-13: Veneno Technologies - Veneno Suite Components
Figure 9-14: Veneno Technologies - Veneno Suite Process
Figure 9-15: Peptron - SmartDepot™ Features
Figure 9-16: Peptron - SmartDepot™ Manufacturing Scheme
Figure 9-17: Bicycle Therapeutics – Bicycles Key Properties
Figure 9-18: Bicycle Therapeutics – Bicycles Key Properties
Figure 9-19: pHion Therapeutics - RALA Nanoparticles Advantages
Figure 9-20: pHion Therapeutics - RALA Nanoparticles BENEFITS
Figure 9-21: Orbit Discovery - Orbit Peptide Display Engine
Figure 9-22: Benefits of Imotopes over Current Therapies
Figure 9-23: Peptilogics – Peptide Development Process
Figure 9-24: Peptilogics - Nautilus Features
Figure 9-25: Pepticom - Swarm Intelligence 2.0 AI platform
Figure 9-26: Cybrexa – alphalex Selective Tumor Cell Targeting
12. LIST OF TABLES
Table 1- 1: Landmarks in Peptides Drugs Market
Table 6-1: US - Recent FDA Designations for Peptide Drug Candidates
Table 8-1: Bylvay - Recommended Dosage for 40 mcg/kg/day
Table 8-2: Parsabiv - Recommended Schedule for Monitoring Corrected Serum
Calcium and Parathyroid Hormone Levels during Treatment
Table 8-3: Voxzogo - Recommended Daily Dosage and Injection Volume
Table 8-4: Wegovy - Recommended Dosage Regimen for Adults
Table 8-5: Wegovy - Recommended Dosage Regimen for Pediatric Patients Aged
Years and Older
Table 9-1: GenScript - PepPower™ Platform Advantages
